CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,299,058 | +28.5% | 28,620 | +58.9% | 0.00% | – |
| Q2 2023 | $1,011,246 | +14.4% | 18,013 | -7.8% | 0.00% | – |
| Q1 2023 | $883,791 | -11.2% | 19,540 | -20.2% | 0.00% | -100.0% |
| Q4 2022 | $995,312 | -30.3% | 24,485 | +12.1% | 0.00% | 0.0% |
| Q3 2022 | $1,427,000 | +7.6% | 21,842 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $1,326,000 | +10.7% | 21,828 | +14.3% | 0.00% | 0.0% |
| Q1 2022 | $1,198,000 | -3.7% | 19,089 | +16.2% | 0.00% | 0.0% |
| Q4 2021 | $1,244,000 | -29.9% | 16,421 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $1,775,000 | -49.2% | 15,855 | -26.6% | 0.00% | -50.0% |
| Q2 2021 | $3,495,000 | +80.0% | 21,591 | +35.5% | 0.00% | +100.0% |
| Q1 2021 | $1,942,000 | +33.8% | 15,935 | +68.1% | 0.00% | 0.0% |
| Q4 2020 | $1,451,000 | +330.6% | 9,478 | +135.4% | 0.00% | – |
| Q3 2020 | $337,000 | – | 4,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |